In order to bring you the best possible user experience, this site uses Javascript. If you are seeing this message, it is likely that the Javascript option in your browser is disabled. For optimal viewing of this site, please ensure that Javascript is enabled for your browser.


The free consultation period for this content is over.

It is now only available year-round to HFA Silver & Gold Members, Fellows of the ESC and Young combined Members

Impact of environmental factors on heart failure decompensations

Session Rapid Fire 1 - Basic Science

Speaker Vanessa Escolar Perez

Congress : Heart Failure 2019

  • Topic : heart failure
  • Sub-topic : Chronic Heart Failure - Epidemiology, Prognosis, Outcome
  • Session type : Rapid Fire Abstracts
  • FP Number : 14

Authors : V Escolar Perez (Bilbao,ES), A Lozano (Bilbao,ES), N Larburu (San Sebastián,ES), G Artola (San Sebastián,ES), R Alvarez (San Sebastián,ES), B Juez (Bilbao,ES), J Kerexeta (San Sebastián,ES), A Artetxe (San Sebastián,ES), A Echebarria (San Sebastián,ES), A Azcona (San Sebastián,ES)

Authors:
V Escolar Perez1 , A Lozano1 , N Larburu2 , G Artola2 , R Alvarez2 , B Juez3 , J Kerexeta2 , A Artetxe2 , A Echebarria2 , A Azcona2 , 1Hospital de Basurto, Cardiology - Bilbao - Spain , 2Vicomtech Research Centre - San Sebastián - Spain , 3Hospital de Basurto - Bilbao - Spain ,

Citation:

Introduction: The association of environmental pollution and weather changes in the development and decompensation of heart failure (HF) is not well studied.

Objectives and methods: The objective is to determine the impact of various environmental factors on the decompensation of heart failure. The following data have been collected: 1. Hospital admissions for heart failure in our hospital from January 2012 to August 2017. 2. Weather registry (wind, temperature, humidity, rainfall, atmospheric pressure) in that period (data from Euskalmet, the Basque agency of meteorology). 3. Air quality (% of carbon monoxide, nitric oxide, nitrogen oxide and dioxide, pollution and particulate matter -PM10-, sulphur dioxide, benzenes and toluenes) (data from Open Data Euskadi website).

Results: The database contains 8338 hospitalizations of 5343 different patients (average of 4.02 admissions per day). In the warmer months (June to October) there are significantly fewer hospital admissions due to worsening HF than in the colder months (December to March). The parameter that best predicts HF decompensation is a previous hospital admission due to the same cause (table 1). Within environmental factors, the attribute that best correlates with HF decompensations is temperature, so the lower the temperature, the greater the risk (inverse correlation - Figure 1). The concentrations of sulphur dioxide and nitrogen oxide have a positive correlation with decompensations. Humidity, precipitation and PM10 parameters have not shown significant correlation or relevant p values.

Conclusions: There is a clear relationship between environmental factors and heart failure decompensations. The most relevant being factors are temperature (inverse relationship) and air composition (percentage of sulphur dioxide and nitrogen oxide).

Correlation

P value

Previous hospital admissions

0.7075

0.002

Temperature

-0.3794

0.014

Humidity

0.0469

0.238

Precipitation

0.0795

0.046

SO2

0.23

0.007

NOX

0.2196

<0.001

NO

0.1733

<0.001

NO2

0.1876

<0.001

PM10

-0.0485

0.324

The free consultation period for this content is over.

It is now only available year-round to HFA Silver & Gold Members, Fellows of the ESC and Young combined Members



Based on your interests

Members get more

Join now
  • 1ESC Professional Members – access all resources from ESC Congress and ESC Asia with APSC & AFC
  • 2ESC Association Members (Ivory, Silver, Gold) – access your Association’s congress resources
  • 3Under 40 or in training - with a Combined Membership, access resources from all congresses
Join now

Our sponsors

ESC 365 is supported by Bayer, Boehringer Ingelheim and Lilly Alliance, Bristol-Myers Squibb and Pfizer Alliance, Novartis Pharma AG and Vifor Pharma in the form of educational grants. The sponsors were not involved in the development of this platform and had no influence on its content.

logo esc

Our mission: To reduce the burden of cardiovascular disease

Who we are